600211 西藏药业
已收盘 04-30 15:00:00
资讯
新帖
简况
西藏药业(600211)3月31日股东户数4.31万户,较上期增加0.7%
证券之星 · 04-28 17:31
西藏药业(600211)3月31日股东户数4.31万户,较上期增加0.7%
每周股票复盘:西藏药业(600211)华西药业质押展期1,876万股
证券之星 · 04-19
每周股票复盘:西藏药业(600211)华西药业质押展期1,876万股
中国经济网报道 | 扎根雪域守初心 锚定双径谋发展 西藏药业勇担“西藏的药业”时代使命
市场资讯 · 04-16
中国经济网报道 | 扎根雪域守初心 锚定双径谋发展 西藏药业勇担“西藏的药业”时代使命
每周股票复盘:西藏药业(600211)将召开2025年年度股东会
证券之星 · 04-12
每周股票复盘:西藏药业(600211)将召开2025年年度股东会
西藏药业(600211)披露2025年年度股东会召开提示性公告,4月7日股价下跌0.19%
证券之星 · 04-07
西藏药业(600211)披露2025年年度股东会召开提示性公告,4月7日股价下跌0.19%
每周股票复盘:西藏药业(600211)回购耗资1.78亿拟用于股权激励
证券之星 · 04-05
每周股票复盘:西藏药业(600211)回购耗资1.78亿拟用于股权激励
股市必读:西藏药业(600211)3月23日收盘跌7.02%,主力净流出1183.84万元
证券之星 · 03-24
股市必读:西藏药业(600211)3月23日收盘跌7.02%,主力净流出1183.84万元
花旗:维持康哲药业“买入”评级 目标价上调至17.5港元
智通财经 · 03-18
花旗:维持康哲药业“买入”评级 目标价上调至17.5港元
西藏药业(600211.SH)发布2025年度业绩,归母净利润9.38亿元,同比下降10.78%
智通财经 · 03-12
西藏药业(600211.SH)发布2025年度业绩,归母净利润9.38亿元,同比下降10.78%
每周股票复盘:西藏药业(600211)回购金额达1.78亿元,占总股本1.24%
证券之星 · 03-08
每周股票复盘:西藏药业(600211)回购金额达1.78亿元,占总股本1.24%
西藏药业(600211)披露回购股份进展公告,3月2日股价下跌1.13%
证券之星 · 03-02
西藏药业(600211)披露回购股份进展公告,3月2日股价下跌1.13%
每周股票复盘:西藏药业(600211)子公司担保议案获股东会通过
证券之星 · 03-01
每周股票复盘:西藏药业(600211)子公司担保议案获股东会通过
西藏药业(600211)披露2026年第一次临时股东会决议公告,2月25日股价上涨1.51%
证券之星 · 02-25
西藏药业(600211)披露2026年第一次临时股东会决议公告,2月25日股价上涨1.51%
每周股票复盘:西藏药业(600211)回购金额达1.78亿元,占总股本1.24%
证券之星 · 02-08
每周股票复盘:西藏药业(600211)回购金额达1.78亿元,占总股本1.24%
西藏药业(600211)披露关于控股子公司提供担保的议案,2月5日股价上涨0.48%
证券之星 · 02-05
西藏药业(600211)披露关于控股子公司提供担保的议案,2月5日股价上涨0.48%
西藏药业(600211)披露回购股份进展公告,2月3日股价上涨1.09%
证券之星 · 02-03
西藏药业(600211)披露回购股份进展公告,2月3日股价上涨1.09%
每周股票复盘:西藏药业(600211)股份回购达总股本1.02%
证券之星 · 01-25
每周股票复盘:西藏药业(600211)股份回购达总股本1.02%
西藏药业(600211)披露股份回购达到1%的进展公告,1月20日股价下跌0.3%
证券之星 · 01-20
西藏药业(600211)披露股份回购达到1%的进展公告,1月20日股价下跌0.3%
每周股票复盘:西藏药业(600211)首次回购股份3800股,耗资16.33万元
证券之星 · 01-11
每周股票复盘:西藏药业(600211)首次回购股份3800股,耗资16.33万元
西藏药业(600211)披露为控股子公司提供担保进展公告,01月07日股价下跌0.32%
证券之星 · 01-07
西藏药业(600211)披露为控股子公司提供担保进展公告,01月07日股价下跌0.32%
加载更多
公司概况
公司名称:
西藏诺迪康药业股份有限公司
所属行业:
医药制造业
上市日期:
1999-07-21
主营业务:
西藏诺迪康药业股份有限公司的主营业务是生产、销售胶囊剂、生物制剂、颗粒剂、涂膜剂等。公司的主要产品是新活素、依姆多、诺迪康、十味蒂达胶囊、雪山金罗汉止痛涂膜剂、小儿双清颗粒。近年来,公司先后荣获“西藏自治区专精特新中小企业”“主板上市公司价值100强”“农业产业化国家重点龙头企业”、中国创新药价值排行榜双榜:“综合实力榜TOP50”与“生物药榜TOP20”“2025大健康卓越竞争力上市公司”,连续荣获“金牛最具投资价值奖”“上市公司董事会秘书履职评价4A评级”等多项荣誉。
发行价格:
6.00
{"stockData":{"symbol":"600211","market":"SH","secType":"STK","nameCN":"西藏药业","latestPrice":40.46,"timestamp":1777532401000,"preClose":41.19,"halted":0,"volume":3468390,"delay":0,"changeRate":-0.0177,"floatShares":322000000,"shares":322000000,"eps":3.0013,"marketStatus":"已收盘","change":-0.73,"latestTime":"04-30 15:00:00","open":41.06,"high":41.19,"low":40.33,"amount":141000000,"amplitude":0.0209,"askPrice":40.48,"askSize":2,"bidPrice":40.46,"bidSize":496,"shortable":0,"etf":0,"ttmEps":3.0013,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1778031000000},"marketStatusCode":5,"adr":0,"adjPreClose":41.19,"symbolType":"stock","openAndCloseTimeList":[[1777512600000,1777519800000],[1777525200000,1777532400000]],"highLimit":45.31,"lowLimit":37.07,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":322319196,"isCdr":false,"pbRate":3.34,"roa":"--","peRate":13.480825,"roe":"7.58%","epsLYR":2.91,"committee":0.759551,"marketValue":13041000000,"turnoverRate":0.0108,"status":1,"floatMarketCap":13041000000},"requestUrl":"/m/hq/s/600211","defaultTab":"news","newsList":[{"id":"2630374838","title":"西藏药业(600211)3月31日股东户数4.31万户,较上期增加0.7%","url":"https://stock-news.laohu8.com/highlight/detail?id=2630374838","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630374838?lang=zh_cn&edition=full","pubTime":"2026-04-28 17:31","pubTimestamp":1777368705,"startTime":"0","endTime":"0","summary":"证券之星消息,近日西藏药业披露,截至2026年3月31日公司股东户数为4.31万户,较2月28日增加301.0户,增幅为0.7%。在生物制品行业个股中,西藏药业股东户数高于行业平均水平,截至3月31日,生物制品行业平均股东户数为3.56万户。从股价来看,2026年2月28日至2026年3月31日,西藏药业区间跌幅为4.7%,在此期间股东户数增加301.0户,增幅为0.7%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042800051260.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","600211","BK0033"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628725759","title":"每周股票复盘:西藏药业(600211)华西药业质押展期1,876万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2628725759","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628725759?lang=zh_cn&edition=full","pubTime":"2026-04-19 03:12","pubTimestamp":1776539529,"startTime":"0","endTime":"0","summary":"截至2026年4月17日收盘,西藏药业报收于41.89元,较上周的42.26元下跌0.88%。本周,西藏药业4月15日盘中最高价报42.63元。4月14日盘中最低价报40.89元。西藏药业当前最新总市值135.02亿元,在生物制品板块市值排名23/51,在两市A股市值排名1554/5198。本次股份质押展期1,876万股,占其所持股份的33.41%,占公司总股本的5.82%。截至公告日,华西药业累计质押股份1,876万股,无限售和冻结情况。华西药业生产经营正常,具备履约能力。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041900001101.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","600211","BK0033"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627429322","title":"中国经济网报道 | 扎根雪域守初心 锚定双径谋发展 西藏药业勇担“西藏的药业”时代使命","url":"https://stock-news.laohu8.com/highlight/detail?id=2627429322","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627429322?lang=zh_cn&edition=full","pubTime":"2026-04-16 16:52","pubTimestamp":1776329520,"startTime":"0","endTime":"0","summary":"(来源:西藏药业)\n\n\n海量资讯、精准解读,尽在新浪财经APP","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/wm/2026-04-16/doc-inhusvkh1594771.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4614","BK4588","600211","BK0239","HXC","BK4504","ASHS","ASHR","BK0033","KWEB","BK4585","LU0963586101.USD","DRAG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626812217","title":"每周股票复盘:西藏药业(600211)将召开2025年年度股东会","url":"https://stock-news.laohu8.com/highlight/detail?id=2626812217","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2626812217?lang=zh_cn&edition=full","pubTime":"2026-04-12 02:04","pubTimestamp":1775930653,"startTime":"0","endTime":"0","summary":"截至2026年4月10日收盘,西藏药业报收于42.26元,较上周的42.0元上涨0.62%。本周,西藏药业4月10日盘中最高价报42.77元。西藏药业当前最新总市值136.21亿元,在生物制品板块市值排名23/51,在两市A股市值排名1502/5196。公司公告汇总西藏诺迪康药业股份有限公司将于2026年4月13日召开2025年年度股东会,会议采取现场投票与网络投票相结合方式,股权登记日为2026年4月2日。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041200000557.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0033","600211"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625995939","title":"西藏药业(600211)披露2025年年度股东会召开提示性公告,4月7日股价下跌0.19%","url":"https://stock-news.laohu8.com/highlight/detail?id=2625995939","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625995939?lang=zh_cn&edition=full","pubTime":"2026-04-07 17:40","pubTimestamp":1775554833,"startTime":"0","endTime":"0","summary":"截至2026年4月7日收盘,西藏药业报收于41.92元,较前一交易日下跌0.19%,最新总市值为135.12亿元。该股当日开盘42.04元,最高42.62元,最低41.3元,成交额达1.02亿元,换手率为0.75%。西藏诺迪康药业股份有限公司于近日发布《关于召开2025年年度股东会的提示性公告》。公告显示,公司定于2026年4月13日召开2025年年度股东会,会议采取现场投票与网络投票相结合方式,股权登记日为2026年4月2日。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040700024556.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0033","600211","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625619806","title":"每周股票复盘:西藏药业(600211)回购耗资1.78亿拟用于股权激励","url":"https://stock-news.laohu8.com/highlight/detail?id=2625619806","media":"证券之星","labels":["buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625619806?lang=zh_cn&edition=full","pubTime":"2026-04-05 02:47","pubTimestamp":1775328427,"startTime":"0","endTime":"0","summary":"截至2026年4月3日收盘,西藏药业报收于42.0元,较上周的40.82元上涨2.89%。本周,西藏药业4月2日盘中最高价报43.43元。回购股份拟用于员工持股计划或股权激励。业绩披露要点西藏诺迪康药业股份有限公司2025年年度报告及董事会工作报告显示,公司2025年实现营业收入29.82亿元,同比增长6.23%;归属于上市公司股东的净利润9.38亿元,同比下降10.78%,主要因其他收益减少。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040500000720.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0033","600211","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621085211","title":"股市必读:西藏药业(600211)3月23日收盘跌7.02%,主力净流出1183.84万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2621085211","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621085211?lang=zh_cn&edition=full","pubTime":"2026-03-24 02:18","pubTimestamp":1774289895,"startTime":"0","endTime":"0","summary":"截至2026年3月23日收盘,西藏药业报收于39.44元,下跌7.02%,换手率2.15%,成交量6.93万手,成交额2.79亿元。来自资金流向:3月23日主力资金净流出1183.84万元,占总成交额4.25%。交易信息汇总股价提醒3月23日西藏药业收盘报39.44元,跌7.02%,当日成交692.88万元。该股已连续3日下跌。前10个交易日主力资金累计净流出5729.22万元,股价累计下跌5.5%;融资余额累计减少176.42万元,融券余量累计增加2.29万股。最近90天内共有1家机构给出评级,均为买入评级。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032400002095.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0033","600211"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620528572","title":"花旗:维持康哲药业“买入”评级 目标价上调至17.5港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2620528572","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620528572?lang=zh_cn&edition=full","pubTime":"2026-03-18 11:29","pubTimestamp":1773804540,"startTime":"0","endTime":"0","summary":"花旗发布研报称,维持康哲药业(00867)“买入”评级,根据管理层最新对创新药快速增长的指引,该行上调2026及2027年收入预测1%及4%,每股盈利预测上调1%及13%;将目标价由16.6港元上调至17.5 ...","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/hks/20260318/c675372644.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["BK0033","600211","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618138455","title":"西藏药业(600211.SH)发布2025年度业绩,归母净利润9.38亿元,同比下降10.78%","url":"https://stock-news.laohu8.com/highlight/detail?id=2618138455","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618138455?lang=zh_cn&edition=full","pubTime":"2026-03-12 18:05","pubTimestamp":1773309928,"startTime":"0","endTime":"0","summary":"智通财经APP讯,西藏药业(600211.SH)披露2025年年度报告,报告期公司实现营收29.82亿元,同比增长6.23%;归属于上市公司股东的净利润9.38亿元,同比下降10.78%;扣非净利润8.71亿元,同比增长1.48%;基本每股收益2.91元。公司拟向全体股东按每10股派发现金8.76元(含税)。报告期内,在宏观环境复杂多变、产业政策动态演进的背景下,深入贯彻董事会战略部署,积极适应新时期的新要求,提升内部管理水平、拓展销售渠道、挖掘市场潜力、注重人才培养和团队建设,坚持以公司战略目标和年度经营目标为指引,按计划有序开展各项经营工作,公司经营情况总体保持平稳。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1413163.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"西藏药业(600211.SH)发布2025年度业绩,归母净利润9.38亿元,同比下降10.78%","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["600211"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617266359","title":"每周股票复盘:西藏药业(600211)回购金额达1.78亿元,占总股本1.24%","url":"https://stock-news.laohu8.com/highlight/detail?id=2617266359","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617266359?lang=zh_cn&edition=full","pubTime":"2026-03-08 03:09","pubTimestamp":1772910551,"startTime":"0","endTime":"0","summary":"截至2026年3月6日收盘,西藏药业报收于42.43元,较上周的42.58元下跌0.35%。本周,西藏药业3月3日盘中最高价报42.78元。西藏药业当前最新总市值136.76亿元,在生物制品板块市值排名22/51,在两市A股市值排名1553/5190。本周关注点公司公告汇总:截至2026年2月底,公司累计回购股份4,000,058股,占总股本的1.24%,已支付总金额177,595,651.46元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030800001094.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600211","BK0239","BK0033"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616356863","title":"西藏药业(600211)披露回购股份进展公告,3月2日股价下跌1.13%","url":"https://stock-news.laohu8.com/highlight/detail?id=2616356863","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616356863?lang=zh_cn&edition=full","pubTime":"2026-03-02 22:56","pubTimestamp":1772463378,"startTime":"0","endTime":"0","summary":"截至2026年3月2日收盘,西藏药业报收于42.1元,较前一交易日下跌1.13%,最新总市值为135.7亿元。西藏药业近日披露《关于回购股份的进展公告》。公告显示,公司于2025年12月18日召开董事会,审议通过以集中竞价交易方式回购股份的议案,回购资金总额不低于17,000万元且不高于20,000万元,回购价格不超过55元/股,回购期限为2025年12月18日至2026年12月17日。回购股份拟用于员工持股计划或股权激励。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030200040223.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600211","BK0239","BK0033"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616843269","title":"每周股票复盘:西藏药业(600211)子公司担保议案获股东会通过","url":"https://stock-news.laohu8.com/highlight/detail?id=2616843269","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616843269?lang=zh_cn&edition=full","pubTime":"2026-03-01 02:14","pubTimestamp":1772302451,"startTime":"0","endTime":"0","summary":"截至2026年2月27日收盘,西藏药业报收于42.58元,较上周的41.74元上涨2.01%。本周,西藏药业2月25日盘中最高价报42.78元。本次股东会于2026年2月25日召开,采用现场与网络投票相结合方式,审议通过关于公司控股子公司提供担保的议案。表决结果显示,同意股数占参会股东所持表决权的99.71%,议案获通过,其中中小投资者对议案的同意率为81.86%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030100000716.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0033","600211"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614033982","title":"西藏药业(600211)披露2026年第一次临时股东会决议公告,2月25日股价上涨1.51%","url":"https://stock-news.laohu8.com/highlight/detail?id=2614033982","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614033982?lang=zh_cn&edition=full","pubTime":"2026-02-25 22:21","pubTimestamp":1772029278,"startTime":"0","endTime":"0","summary":"截至2026年2月25日收盘,西藏药业报收于42.45元,较前一交易日上涨1.51%,最新总市值为136.82亿元。该股当日开盘42.08元,最高42.78元,最低41.81元,成交额达1.26亿元,换手率为0.92%。近日,西藏药业发布《西藏诺迪康药业股份有限公司2026年第一次临时股东会决议公告》。公告显示,公司于2026年2月25日在成都召开2026年第一次临时股东会,出席会议的股东及代理人共446人,代表有表决权股份总数179,455,251股,占公司有表决权股份总数的55.6762%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026022500038071.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0033","600211"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2609525592","title":"每周股票复盘:西藏药业(600211)回购金额达1.78亿元,占总股本1.24%","url":"https://stock-news.laohu8.com/highlight/detail?id=2609525592","media":"证券之星","labels":["buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609525592?lang=zh_cn&edition=full","pubTime":"2026-02-08 01:50","pubTimestamp":1770486622,"startTime":"0","endTime":"0","summary":"截至2026年2月6日收盘,西藏药业报收于42.77元,较上周的42.4元上涨0.87%。本周,西藏药业2月6日盘中最高价报43.6元。截至2026年1月月底,公司累计回购股份4,000,058股,占公司总股本的1.24%,已支付总金额177,595,651.46元,回购最高价为45.98元/股,最低价为42.66元/股。截至公告日,公司及控股子公司对外担保总额为80,000万元,占最近一期经审计净资产的20.24%,无逾期担保。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020800000424.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600211","BK0239","BK0033"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2609301332","title":"西藏药业(600211)披露关于控股子公司提供担保的议案,2月5日股价上涨0.48%","url":"https://stock-news.laohu8.com/highlight/detail?id=2609301332","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609301332?lang=zh_cn&edition=full","pubTime":"2026-02-05 22:36","pubTimestamp":1770302180,"startTime":"0","endTime":"0","summary":"截至2026年2月5日收盘,西藏药业报收于42.17元,较前一交易日上涨0.48%,最新总市值为135.92亿元。该股当日开盘41.97元,最高42.33元,最低41.86元,成交额达1.01亿元,换手率为0.74%。近日,西藏药业发布《关于召开2026年第一次临时股东会的通知》。会议将审议《关于公司控股子公司提供担保的议案》,该议案将对中小投资者单独计票。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020500039840.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0033","600211","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2608453877","title":"西藏药业(600211)披露回购股份进展公告,2月3日股价上涨1.09%","url":"https://stock-news.laohu8.com/highlight/detail?id=2608453877","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608453877?lang=zh_cn&edition=full","pubTime":"2026-02-03 22:36","pubTimestamp":1770129380,"startTime":"0","endTime":"0","summary":"西藏诺迪康药业股份有限公司近日披露《关于回购股份的进展公告》。公告显示,公司于2025年12月18日召开董事会,审议通过以集中竞价交易方式回购股份的议案,回购资金总额不低于17,000万元且不高于20,000万元,回购价格不超过55元/股,回购期限为2025年12月18日至2026年12月17日。本次回购股份用于员工持股计划或股权激励。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020300043351.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600211","BK0239","BK0033"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2606234174","title":"每周股票复盘:西藏药业(600211)股份回购达总股本1.02%","url":"https://stock-news.laohu8.com/highlight/detail?id=2606234174","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606234174?lang=zh_cn&edition=full","pubTime":"2026-01-25 01:49","pubTimestamp":1769276950,"startTime":"0","endTime":"0","summary":"截至2026年1月23日收盘,西藏药业报收于43.95元,较上周的43.79元上涨0.37%。本周,西藏药业1月21日盘中最高价报44.78元。西藏药业当前最新总市值141.66亿元,在生物制品板块市值排名22/51,在两市A股市值排名1529/5182。本次回购股份将用于员工持股计划或股权激励。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012500000389.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0033","600211"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2604111672","title":"西藏药业(600211)披露股份回购达到1%的进展公告,1月20日股价下跌0.3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2604111672","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2604111672?lang=zh_cn&edition=full","pubTime":"2026-01-20 22:24","pubTimestamp":1768919055,"startTime":"0","endTime":"0","summary":"截至2026年1月20日收盘,西藏药业报收于43.9元,较前一交易日下跌0.3%,最新总市值为141.5亿元。该股当日开盘44.07元,最高44.21元,最低43.7元,成交额达1.1亿元,换手率为0.77%。公司近日发布公告称,西藏诺迪康药业股份有限公司于2025年12月18日召开董事会,审议通过以集中竞价交易方式回购股份的议案,回购资金总额不低于17,000万元且不高于20,000万元,回购价格不超过55元/股,回购期限为2025年12月18日至2026年12月17日。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012000039675.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600211","BK0239","BK0033"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2602536510","title":"每周股票复盘:西藏药业(600211)首次回购股份3800股,耗资16.33万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2602536510","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602536510?lang=zh_cn&edition=full","pubTime":"2026-01-11 03:44","pubTimestamp":1768074249,"startTime":"0","endTime":"0","summary":"截至2026年1月9日收盘,西藏药业报收于44.96元,较上周的42.55元上涨5.66%。本周,西藏药业1月9日盘中最高价报44.98元。公司为全资子公司西藏诺迪康生物医药销售有限公司和控股子公司西藏诺迪康医药有限公司分别提供5119.71万元和10000万元的连带责任保证担保,上述担保事项在前期审批额度内,并已获得反担保。截至公告日,公司及控股子公司对外担保总额为80,000万元,占最近一期经审计净资产的20.24%,无逾期担保。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011100001134.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","600211","BK0033"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2601801820","title":"西藏药业(600211)披露为控股子公司提供担保进展公告,01月07日股价下跌0.32%","url":"https://stock-news.laohu8.com/highlight/detail?id=2601801820","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601801820?lang=zh_cn&edition=full","pubTime":"2026-01-07 22:24","pubTimestamp":1767795863,"startTime":"0","endTime":"0","summary":"截至2026年1月7日收盘,西藏药业报收于44.05元,较前一交易日下跌0.32%,最新总市值为141.98亿元。公司近日发布公告称,西藏诺迪康药业股份有限公司为全资子公司西藏诺迪康生物医药销售有限公司和控股子公司西藏诺迪康医药有限公司分别提供5119.71万元和10000万元的连带责任保证担保,担保事项已在前期审批额度内,且已获得反担保。截至公告日,公司及控股子公司对外担保总额为80,000万元,占最近一期经审计净资产的20.24%,无逾期担保。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010700038943.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0033","BK0239","600211"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1777537421194,"stockEarnings":[{"period":"1week","weight":-0.0041},{"period":"1month","weight":0.0066},{"period":"3month","weight":-0.0376},{"period":"6month","weight":-0.1129},{"period":"1year","weight":0.1747},{"period":"ytd","weight":-0.032}],"compareEarnings":[{"period":"1week","weight":0.0003},{"period":"1month","weight":0.047},{"period":"3month","weight":-0.0121},{"period":"6month","weight":0.0386},{"period":"1year","weight":0.2498},{"period":"ytd","weight":0.0349}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"西藏诺迪康药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"43143人(较上一季度增加0.70%)","perCapita":"7470股","listingDate":"1999-07-21","address":"西藏自治区拉萨市堆龙德庆区经济技术开发区A区广州路3号","registeredCapital":"32231万元","survey":" 西藏诺迪康药业股份有限公司的主营业务是生产、销售胶囊剂、生物制剂、颗粒剂、涂膜剂等。公司的主要产品是新活素、依姆多、诺迪康、十味蒂达胶囊、雪山金罗汉止痛涂膜剂、小儿双清颗粒。近年来,公司先后荣获“西藏自治区专精特新中小企业”“主板上市公司价值100强”“农业产业化国家重点龙头企业”、中国创新药价值排行榜双榜:“综合实力榜TOP50”与“生物药榜TOP20”“2025大健康卓越竞争力上市公司”,连续荣获“金牛最具投资价值奖”“上市公司董事会秘书履职评价4A评级”等多项荣誉。","listedPrice":6},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.1","shortVersion":"4.42.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"西藏药业(600211)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供西藏药业(600211)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"西藏药业,600211,西藏药业股票,西藏药业股票老虎,西藏药业股票老虎国际,西藏药业行情,西藏药业股票行情,西藏药业股价,西藏药业股市,西藏药业股票价格,西藏药业股票交易,西藏药业股票购买,西藏药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"西藏药业(600211)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供西藏药业(600211)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}